Digital PCR a Priority for RainDance Following $37.5M Financing

RainDance hopes to be taking pre-orders for a new digital PCR product by the end of this year, and in the meantime is collaborating with academic and industrial partners to refine the technology and develop new applications in the areas of oncology, infectious disease, and immune monitoring.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.